Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Gain Therapeutics, Inc. stock logo
GANX
Gain Therapeutics
$1.93
+9.0%
$1.85
$0.89
$3.19
$57.05M0.17310,226 shs144,256 shs
Moleculin Biotech, Inc. stock logo
MBRX
Moleculin Biotech
$0.91
+4.6%
$0.94
$0.40
$4.90
$12.85M1.641.47 million shs249,745 shs
Outlook Therapeutics, Inc. stock logo
OTLK
Outlook Therapeutics
$1.77
-3.8%
$1.48
$0.87
$9.25
$59.42M0.39778,082 shs1.75 million shs
VolitionRx Limited stock logo
VNRX
VolitionRx
$0.53
+5.2%
$0.50
$0.40
$0.90
$54.50M1186,846 shs437,261 shs
10 "Recession Proof" Stocks That Will Thrive in Any Market Cover

Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Gain Therapeutics, Inc. stock logo
GANX
Gain Therapeutics
0.00%-1.39%-13.83%-8.97%-30.39%
Moleculin Biotech, Inc. stock logo
MBRX
Moleculin Biotech
0.00%-5.72%-12.95%-22.03%-81.20%
Outlook Therapeutics, Inc. stock logo
OTLK
Outlook Therapeutics
0.00%+15.63%+19.35%+30.28%-73.83%
VolitionRx Limited stock logo
VNRX
VolitionRx
0.00%-2.42%+5.89%-18.61%-28.72%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Gain Therapeutics, Inc. stock logo
GANX
Gain Therapeutics
2.5707 of 5 stars
3.64.00.00.02.90.00.6
Moleculin Biotech, Inc. stock logo
MBRX
Moleculin Biotech
1.9885 of 5 stars
3.52.00.00.01.90.01.3
Outlook Therapeutics, Inc. stock logo
OTLK
Outlook Therapeutics
1.8354 of 5 stars
3.43.00.00.01.90.00.6
VolitionRx Limited stock logo
VNRX
VolitionRx
1.3889 of 5 stars
3.30.00.00.00.62.50.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Gain Therapeutics, Inc. stock logo
GANX
Gain Therapeutics
3.17
Buy$8.20324.87% Upside
Moleculin Biotech, Inc. stock logo
MBRX
Moleculin Biotech
3.00
Buy$6.00559.41% Upside
Outlook Therapeutics, Inc. stock logo
OTLK
Outlook Therapeutics
2.80
Moderate Buy$10.20476.27% Upside
VolitionRx Limited stock logo
VNRX
VolitionRx
2.67
Moderate Buy$3.75608.88% Upside

Current Analyst Ratings Breakdown

Latest MBRX, OTLK, GANX, and VNRX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/20/2025
Outlook Therapeutics, Inc. stock logo
OTLK
Outlook Therapeutics
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy
5/19/2025
Gain Therapeutics, Inc. stock logo
GANX
Gain Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$8.00 ➝ $8.00
4/30/2025
VolitionRx Limited stock logo
VNRX
VolitionRx
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$5.00 ➝ $5.00
4/8/2025
VolitionRx Limited stock logo
VNRX
VolitionRx
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy ➝ Buy$2.50 ➝ $2.50
3/31/2025
VolitionRx Limited stock logo
VNRX
VolitionRx
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$5.00 ➝ $5.00
3/28/2025
Gain Therapeutics, Inc. stock logo
GANX
Gain Therapeutics
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$6.00 ➝ $6.00
3/25/2025
Moleculin Biotech, Inc. stock logo
MBRX
Moleculin Biotech
Maxim Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold ➝ Buy$4.00
3/24/2025
Moleculin Biotech, Inc. stock logo
MBRX
Moleculin Biotech
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$8.00 ➝ $8.00
3/20/2025
VolitionRx Limited stock logo
VNRX
VolitionRx
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$5.00 ➝ $5.00
3/17/2025
Gain Therapeutics, Inc. stock logo
GANX
Gain Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$8.00 ➝ $8.00
3/12/2025
VolitionRx Limited stock logo
VNRX
VolitionRx
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$5.00 ➝ $5.00
(Data available from 6/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Gain Therapeutics, Inc. stock logo
GANX
Gain Therapeutics
$50K1,140.94N/AN/A$0.97 per share1.99
Moleculin Biotech, Inc. stock logo
MBRX
Moleculin Biotech
N/AN/AN/AN/A$11.70 per shareN/A
Outlook Therapeutics, Inc. stock logo
OTLK
Outlook Therapeutics
N/AN/AN/AN/A($1.57) per shareN/A
VolitionRx Limited stock logo
VNRX
VolitionRx
$1.31M41.65N/AN/A($0.11) per share-4.81
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Gain Therapeutics, Inc. stock logo
GANX
Gain Therapeutics
-$22.27M-$0.86N/AN/AN/AN/A-203.91%-128.05%8/14/2025 (Estimated)
Moleculin Biotech, Inc. stock logo
MBRX
Moleculin Biotech
-$29.77MN/A0.00N/AN/AN/A-157.44%-97.16%8/12/2025 (Estimated)
Outlook Therapeutics, Inc. stock logo
OTLK
Outlook Therapeutics
-$75.37M-$0.91N/AN/AN/AN/AN/A-225.12%8/13/2025 (Estimated)
VolitionRx Limited stock logo
VNRX
VolitionRx
-$35.32M-$0.27N/AN/A-2,321.14%N/A-163.39%N/A

Latest MBRX, OTLK, GANX, and VNRX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/15/2025Q2 2025
Outlook Therapeutics, Inc. stock logo
OTLK
Outlook Therapeutics
-$0.55-$0.40+$0.15-$1.50$0.70 millionN/A
5/14/2025Q1 2025
Gain Therapeutics, Inc. stock logo
GANX
Gain Therapeutics
-$0.16-$0.16N/A-$0.16$0.03 millionN/A
5/13/2025Q1 2025
Moleculin Biotech, Inc. stock logo
MBRX
Moleculin Biotech
-$0.71-$0.69+$0.02-$0.69N/AN/A
3/27/2025Q4 2024
Gain Therapeutics, Inc. stock logo
GANX
Gain Therapeutics
-$0.18-$0.11+$0.07-$0.11N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Gain Therapeutics, Inc. stock logo
GANX
Gain Therapeutics
N/AN/AN/AN/AN/A
Moleculin Biotech, Inc. stock logo
MBRX
Moleculin Biotech
N/AN/AN/AN/AN/A
Outlook Therapeutics, Inc. stock logo
OTLK
Outlook Therapeutics
N/AN/AN/AN/AN/A
VolitionRx Limited stock logo
VNRX
VolitionRx
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Gain Therapeutics, Inc. stock logo
GANX
Gain Therapeutics
0.04
2.99
2.99
Moleculin Biotech, Inc. stock logo
MBRX
Moleculin Biotech
N/A
2.08
2.08
Outlook Therapeutics, Inc. stock logo
OTLK
Outlook Therapeutics
N/A
0.32
0.64
VolitionRx Limited stock logo
VNRX
VolitionRx
N/A
0.22
0.22

Institutional Ownership

CompanyInstitutional Ownership
Gain Therapeutics, Inc. stock logo
GANX
Gain Therapeutics
11.97%
Moleculin Biotech, Inc. stock logo
MBRX
Moleculin Biotech
15.52%
Outlook Therapeutics, Inc. stock logo
OTLK
Outlook Therapeutics
11.20%
VolitionRx Limited stock logo
VNRX
VolitionRx
8.09%

Insider Ownership

CompanyInsider Ownership
Gain Therapeutics, Inc. stock logo
GANX
Gain Therapeutics
7.18%
Moleculin Biotech, Inc. stock logo
MBRX
Moleculin Biotech
1.90%
Outlook Therapeutics, Inc. stock logo
OTLK
Outlook Therapeutics
4.80%
VolitionRx Limited stock logo
VNRX
VolitionRx
10.40%
CompanyEmployeesShares OutstandingFree FloatOptionable
Gain Therapeutics, Inc. stock logo
GANX
Gain Therapeutics
2029.56 million23.42 millionOptionable
Moleculin Biotech, Inc. stock logo
MBRX
Moleculin Biotech
2014.13 million3.86 millionNot Optionable
Outlook Therapeutics, Inc. stock logo
OTLK
Outlook Therapeutics
2033.57 million30.48 millionOptionable
VolitionRx Limited stock logo
VNRX
VolitionRx
80103.02 million80.80 millionOptionable

Recent News About These Companies

VolitionRx initiated with a Buy at H.C. Wainwright

New MarketBeat Followers Over Time

Media Sentiment Over Time

Gain Therapeutics stock logo

Gain Therapeutics NASDAQ:GANX

$1.93 +0.16 (+9.04%)
Closing price 04:00 PM Eastern
Extended Trading
$1.96 +0.03 (+1.55%)
As of 04:11 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Gain Therapeutics, Inc., a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease. The company's lead drug candidate, GT-02287 for the treatment of GBA1 Parkinson's disease is being evaluated in a Phase I clinical trials. It also has various small molecule drug candidates, which are in the discovery, research, and preclinical stages for the treatment of Dementia with Lewy Bodies, Alzhiemer's Disease, Gaucher, GM1 Gangliosidosis, Krabbe Disease, Alpha1-Antitrypsun deficiency, and solid tumors. Gain Therapeutics, Inc. was founded in 2017 and is headquartered in Bethesda, Maryland.

Moleculin Biotech stock logo

Moleculin Biotech NASDAQ:MBRX

$0.91 +0.04 (+4.59%)
Closing price 04:00 PM Eastern
Extended Trading
$0.90 0.00 (-0.54%)
As of 04:18 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Moleculin Biotech, Inc., a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin, which is in Phase 1B/2 clinical trials for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma metastasized to the lungs. The company is also developing WP1066, an immune/transcription modulator designed to inhibit phosphorylated signal transducer and activator of transcription and other oncogenic transcription factors targeting brain tumors, and pancreatic and other cancers. In addition, it develops WP1220, an analog of WP1066 for the topical treatment of cutaneous T-cell lymphoma; and WP1122 to treat viruses, as well as cancer indications, including brain tumors, and pancreatic and other cancers. The company was incorporated in 2015 and is headquartered in Houston, Texas.

Outlook Therapeutics stock logo

Outlook Therapeutics NASDAQ:OTLK

$1.77 -0.07 (-3.80%)
Closing price 04:00 PM Eastern
Extended Trading
$1.76 -0.02 (-0.85%)
As of 04:20 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with BioLexis Pte. Ltd. and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.

VolitionRx stock logo

VolitionRx NYSE:VNRX

$0.53 +0.03 (+5.17%)
Closing price 03:58 PM Eastern
Extended Trading
$0.52 0.00 (-0.76%)
As of 04:15 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes. VolitionRx Limited is based in Henderson, Nevada.